Advancing Sales and Clinical Collaboration with the World's Four Major MRI Vendors
Centered on 3T, 5T and 7T multi-nuclear MR systems, advancing the deployment of deuterium metabolic imaging across research and clinical scenarios.
Biosotop announced deeper commercial and translational collaboration with four of the world's leading MRI equipment manufacturers, aiming to accelerate the deployment of “hardware + probe” deuterium metabolic imaging solutions across medical institutions and research institutes at all levels.
Conventional proton (¹H) MRI is mainly used for anatomical imaging. With multi-nuclear MR hardware upgrades combined with Biosotop's proprietary deuterated tracers, clinicians can now not only “see structure clearly” but also “see through metabolism” directly. This major technological leap greatly expands the application boundaries of MR equipment.
Under this strategic plan, the parties will carry out coil adaptation, joint pulse-sequence optimization and co-development of image post-processing software around 3T mainstream clinical systems, 5T innovative systems and 7T ultra-high-field research systems. Biosotop will provide partner hospitals and research centers with full isotope-drug supply-chain support, closing the commercial loop for technology deployment.